| Literature DB >> 35159767 |
Anh-Minh Nguyen1,2, Ana Elena Pradas Del Real3, Olivier Durupthy1, Sophie Lanone2, Corinne Chanéac1, Sophie Carenco1.
Abstract
Acceptability and relevance of nanoparticles in the society is greatly improved using a safer-by-design strategy. However, this is difficult to implement when too late in the development process or when nanoparticles are already on the market (e.g., TiO2). We employ this strategy for emerging nanoparticles of lanthanide oxysulfide of formula (Gd,Ce)2O2S, relevant for photocatalysis as well as for multimodal imaging, as the bandgap of the nanoparticles, related to their Ce content, impacts their ability to absorb visible light. As a first step, we investigated the production of reactive oxygen species (ROS) as a function of cerium content, in abiotic conditions and in vitro using murine macrophage RAW 264.7 cell line. We demonstrate that, at sub-lethal doses, Ce-containing oxysulfide nanoparticles are responsible for a higher ROS intracellular formation than cerium-free Gd2O2S nanoparticles, although no significant inflammatory response or oxidative stress was measured. Moreover, there was no significant loss of cerium as free cation from the nanoparticles, as evidenced by X-ray fluorescence mapping. Based on these results, we propose a risk analysis for lanthanide oxysulfide nanoparticles, leading to a technology assessment that fulfills the safer-by-design strategy.Entities:
Keywords: ROS; cerium; lanthanides; murine macrophage RAW 264.7; nanoparticles; oxysulfides; safer-by-design
Year: 2022 PMID: 35159767 PMCID: PMC8840297 DOI: 10.3390/nano12030422
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Transmission electron microscopy of Gd2O2S (A) and GdCeO2S (B) nanoparticles. In (B), the white square indicates nanoparticles that are staked and observed sideways. (C) Representation of the lamellar cristallographic structure of Gd2O2S. (D) View from the (001) direction of the structure. (E) Environment of Gd/Ce in the structure. (F) Schematic representation of [Ln2O2]2+-terminated Gd2(1−Ce2O2S nanoparticles covered with oleate ligands.
Figure 2UV-visible diffuse reflectance spectra of Gd2O2S and GdCeO2S nanoplatelets. The y-axis is expressed as the Kubelka-Munk function F(R) calculated from obtained apparent absorbance. The dashed line indicates the wavelength at which the following ROS production experiments were carried out.
Figure 3Radical production under irradiation of 501 nm visible light of (a) BiVO4 nanoparticles, (b) Gd2O2S (x = 0%) nanoparticles and (c) GdCeO2S (x = 50%) nanoparticles at different concentrations of photocatalysts. Radical production under irradiation, calculated as difference between the normalized DTT quantities in the dark and under irradiation, is presented as bar graph (right y-axis).
Figure 4Cellular DNA quantification of RAW 264.7 macrophages exposed to Gd2(1−CeO2S and TiO2 P25 nanoparticles at different concentrations during 24 h. The cellular DNA contents were reported as percentages of that of unexposed cells. The experiments were repeated at least three times.
Figure 5WST-1 assay of RAW 264.7 macrophages exposed to Gd2(1−Ce2O2S and TiO2 P25 nanoparticles at different concentrations during 24 h. The mitochondrial activities were reported as percentages of that of unexposed cells. The experiments were repeated at least three times. **** signifies a p-value inferior to 0.0001.
Figure 6Intracellular ROS production of RAW 264.7 cells upon exposure to 10 and 50 µg/mL of Gd2(1−CeO2S nanoparticles (0, 10 and 50% Ce) after 15 min and 45 min. The ROS production was normalized to that of unexposed cells. The experiments were repeated three times. **** indicates a p-value inferior to 0.0001.
Figure 7HO-1 expression of RAW 264.7 cells after 24 h of exposure to 10 µg/mL of Gd2O2S (0% Ce) nanoparticles and GdCeO2S (50% Ce) nanoparticles. Cell treatment with 10 µg/mL of LPS was used as positive control. (a) Results from western blot analysis of HO-1 and β-actin. (b) Average quantities of HO-1 deduced from the intensity of the fluorescent bands of three repeated western blot analyses. They are normalized with the corresponding β-actin quantity.
Figure 8(a–c) Pro-inflammatory cytokines IL-6, IL-1β and TNF-α secretion levels of RAW 264.7 cells treated with 10 µg/mL of Gd2O2S (0% Ce) nanoparticles and GdCeO2S (50% Ce) nanoparticles during 24 h. Cell treatment with 10 µg/mL of LPS was used as positive control.
Figure 9Single-element XRF maps (100 µm × 100 µm) of cells exposed to GdCeO2S (50% Ce) nanoparticles showing distribution of K (top left), Gd (bottom left) and Ce (bottom right). The images are displayed using a linear scale. The values in the color bars represent the concentration of elements in mM. The XRF maps were acquired at 7.4 keV. The merge color-coded map is also presented (top right).
Figure 10Scatter plot of concentration profile of Ce over Gd in XRF map of cells exposed to nanoparticles containing 50% of cerium. The red zones describe the standard deviation of the EDS measurement. The arrows indicate the groups of points that deviate from the linear concentration profile.
Risk Analysis and Technology Assessment of Gd2(1−Ce2O2S nanoparticles inspired from [27] by applying van Wezel methodology [26] for SbD considerations.
| Case Study | Gd2O2S | Gd1.8Ce0.2O2S | GdCeO2S | |
|---|---|---|---|---|
|
| RA1. What is the «nano» aspect of your development? | Crystalline nanoplatelets (2D nanomaterial) [ | ||
| RA2. What is the already known regulatory framework? | CAS: 12339-07-0 | CAS: not yet | CAS: not yet | |
| RA3. What do you already know on the safety aspects? | HARN *: No | HARN *: No | HARN *: No | |
| RA4. Are there any discussion on “nano” within legislative framework? | REACH: 2D nanoform (hazard data between nanoforms and/or sets of nanoforms, and the non-nanoforms of the same substance) *** | |||
| RA5. What are new aspects, related to already authorized products? | Smaller size suggesting better biodistribution of contrast agent and clearance ** | Antioxidant properties that could be adjusted by tuning Ce content ** | Very small semiconductor with strong absorption band in visible ** | |
| RA6. Is your product less risky than existing products regarding solubility? | Less soluble than Gd2O3 | Less soluble than CeO2 | ||
| RA7. Do you have any information on the intrinsic hazardous aspects? | Strong adsorption capability due to surface reactivity and high surface area ** | |||
| No lethal toxicity up to 100 µg/mL ** | Lethal toxicity from 50 µg/mL ** | |||
| RA8. Can material be released in significant quantities during the production, use, or waste phase? | Low dissolution rate and Gd3+ release in water, biologic media and cell compartment at short term but not know at long term ** | |||
| RA9. Do you have information on the environment fate and behavior? | Exposure: consider the very small size of nanoparticles in the exposure scenarios specific to the manufactured products and applications that will use these materials. | |||
| Low ROS production under visible light (501 nm) in water until 1000 µg/mL ** | High ROS production under visible light (501 nm) in water over 100 µg/mL ** | |||
|
| TA1. Which other stakeholders, besides suppliers and customers, could you imagine? | Pharmaceutical laboratory | Pharmaceutical laboratory | Depollution industry |
| TA2. How will these stakeholders be affected in both positive and negative ways? | Insulator material | Semiconductor | Semiconductor | |
| TA3. How does this new technology influence stakeholder’s responsibilities and liabilities? | Potential use for biomedical application with controlled exposure | High reactivity suggesting restricted use for biomedical application—Requires effective surface protection | Application limiting exposure and contact with skin and eyes | |
| TA4. Which different possible futures could you imagine with your development? | Biomedical imaging: MRI contrast agent for diagnosis | Theranostics: mixing antoxidant properties of Ce with magnetic properties of Gd for MRI | Photocatalysis in visible light | |
* High aspect ratio nanoparticles (HARN), the value is given in brackets. ** affirmation deduced from the present study. *** REACH: Appendix R.6-1 for nanoforms applicable to the Guidance on QSARs and Grouping of Chemicals.